VTRS
$13.20-0.30 (-2.22%)
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: ...
Recent News
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year
This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide.
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
What Are Analysts Saying About Viatris Inc (VTRS) Stock?
Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% upside from current levels. On February 27, Truist Financial analyst Les Sulewski raised the firm’s price target on the stock from […]
Assessing Viatris (VTRS) Valuation After Mixed Short And Long Term Share Price Moves
Why Viatris (VTRS) Is On Investors’ Radar Viatris (VTRS) is drawing attention after a mixed stretch in its share performance, with a negative move over the past month but a positive total return over the past 3 months and year. See our latest analysis for Viatris. At a share price of US$13.51, Viatris has recently seen a 16.24% 1 month share price decline after a strong 15.97% 3 month share price return, set against a 55.38% 1 year total shareholder return that hints at shifting sentiment...